AtriCure, Inc. vs Merck & Company, Inc. — Stock Comparison
Q·Score Breakdown
6.7
Neutral
Overall
6.7
Neutral
Quality
Health
Growth
Valuation
Sentiment
ATRC
Clean balance sheet with low leverage (0.2× debt-to-equity).
⚠ currently unprofitable (-2% margin).
MRK
Forward P/E of 11.5× is low relative to sector peers.
Analyst Consensus
BUY
Target $46.75 (+61.1%)
8 analysts
BUY
Target $129.74 (+15.7%)
27 analysts
Fundamentals
ATRC
MRK
—
Trailing P/E
31.5×
78.5×
Forward P/E
11.5×
-2.1%
Profit Margin
13.6%
75.0%
Gross Margin
76.6%
-2.4%
ROE
—
13.1%
Revenue Growth
4.9%
—
Earnings Growth
—
1.43
Beta
0.28
—
Price / Book
—
$1.5B
Market Cap
$277.0B
$27 – $43
52-Week Range
$73 – $125
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →